Ying-Bin Liu
Overview
Explore the profile of Ying-Bin Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
1780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu X, Wang F, Li H, Hu Y, Jiang L, Zhang F, et al.
EMBO Rep
. 2024 Oct;
25(11):5216-5219.
PMID: 39367151
No abstract available.
2.
Zhang W, Wang Y, Liu J, Sun X, Jiang Y, Shen F, et al.
Sci Bull (Beijing)
. 2024 Oct;
69(22):3547-3557.
PMID: 39366826
Biliary tract carcinoma (BTC) is a group of malignant tumors that originate in the digestive system and occurs with a high incidence in China. Few consistent and comparable assessments of...
3.
Liu Y, Qin J, Zeng G
Int J Numer Method Biomed Eng
. 2023 Sep;
39(12):e3776.
PMID: 37776042
Acupuncture points have a positive effect on the auxiliary prevention and treatment of diseases, so medical devices such as acupuncture robots often need to combine acupuncture points to improve the...
4.
Jia Z, Zhu Y, Wu X, Yang J, Wu W, Wang X, et al.
Cancer Med
. 2023 Sep;
12(18):18861-18871.
PMID: 37706628
Background: Three-dimensional visualization preoperative evaluation (3D-VPE) and enhanced recovery after surgery (ERAS) have been suggested to improve outcomes of cancer surgery in patients, yet little is known regarding their clinical...
5.
Yang J, Jia Z, Liu F, Wu W, Li X, Zou L, et al.
Front Oncol
. 2023 Mar;
13:1078388.
PMID: 36969051
Background: Gallbladder cancer (GBC) is highly lethal and resistant to most chemotherapeutic drugs. GBC was reported to carry multiple genetic mutations such as TP53, K-RAS, and ERBB2/3. Here, we unexpectedly...
6.
Shi G, Huang X, Wen T, Song T, Kuang M, Mou H, et al.
Cancer Med
. 2022 Sep;
12(4):4137-4146.
PMID: 36127767
Objective: This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background:...
7.
Wu X, Wang F, Li H, Hu Y, Jiang L, Zhang F, et al.
EMBO Rep
. 2022 Sep;
23(9):e55711.
PMID: 36062313
No abstract available.
8.
Wu X, Wang X, Sun X, Ren T, Zhao L, Shen L, et al.
MedComm (2020)
. 2021 Nov;
1(2):249-252.
PMID: 34766122
No abstract available.
9.
Hu Y, Jin Y, Wu X, Yang Y, Li Y, Li H, et al.
Mol Cancer
. 2021 Aug;
20(1):110.
PMID: 34454521
No abstract available.
10.
Cui X, Li X, Cui J, Wu X, Zou L, Song X, et al.
Hepatobiliary Surg Nutr
. 2021 Aug;
10(4):498-506.
PMID: 34430528
Background: The first-line chemotherapy regimen for advanced gallbladder cancer (GBC) is gemcitabine plus platinum (GP), despite its efficacy is limited. The current investigation is a retrospective study to compare the...